The stock may react positively to revenue growth and stable margins, but investors should monitor cash burn and the pace of integration as operating losses widened significantly despite top-line growth.
Price Chart
Executive Summary
Vivos Therapeutics reported full-year 2025 revenue of $17.4 million, a 16% year-over-year increase driven by the integration of The Sleep Center of Nevada, while gross margin held steady at 60%. The company incurred an operating loss of $19.9 million as it continues to invest in its new business model focused on sleep center acquisitions and alliances.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $17.4 million, up 16% YoY
- Gross margin remained flat at 60%
- Operating loss widened to $19.9 million from $11.2 million in 2024
- Cash balance was $2.0 million as of year-end, augmented by $6.8 million in subsequent financing
- Product revenue declined 18% YoY while service revenue grew 53%, reflecting strategic shift
Financial Impact
Revenue increased by $2.4 million year-over-year, but operating expenses grew faster, increasing losses
Risk Factors
- Operating loss increased 78% year-over-year despite revenue growth
- Reliance on recent financing to sustain operations raises liquidity concerns
- Strategic shift away from product revenue to service revenue carries execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-016865 |
| Document: form8-k.htm | 0001493152-26-016865 |
| Document: 0001493152-26-016865-index-headers.html | 0001493152-26-016865 |
| Document: 0001493152-26-016865-index.html | 0001493152-26-016865 |
| Document: 0001493152-26-016865.txt | 0001493152-26-016865 |
| 8-K Data (Synthetic) | 0001493152-26-016865 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1283 (−4.75%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1283 (−9.01%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1283 (−8.75%) |
Oct 15, 2026 12d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1283 (−10.15%) |
Oct 15, 2026 12d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1283 (−10.15%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1283 (+13.89%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1283 (−42.95%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1283 (−53.65%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1283 (+57.40%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1283 (−62.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers